We would love to hear your thoughts about our site and services, please take our survey here.
This is an excellent announcement. I see SOS enjoying a Boohoo like share price trajectory over the next 3 years.
A miserable day - a day for lazing & dreaming. BTC at $11884. Drift into & out of that land of dreams & on Monday morning GOOGLE bitcoinusd. WHAT !!! Can it be !!! Over $12000 & accelerating !!! ARGO price ? 8p - 9p - 10p.
Forgive a long-term holder his dreams - but sometimes dreams do come true.
Just a few observations here:
> I agree that the CEO's pay [what companies quaintly call compensation - presumably for the effort of getting out of bed], is excessive for a company of this size & at this stage of development. £259K per annum would be more appropriate. After all, i imagine, he also has a shed-load of options gratefully awarded by a compliant remuneration committee.
> EXOSOMES: Somebody with much greater scientific knowledge than i may care to look at Nasdaq quoted Orgenesis - among their various programmes they claim breakthrough progress on Exosomes. How do the two compare in this regard?
> Maybe RENE need the laser sharp focus of American investors. Look how it has transformed the likes of Mereo - Verona & Tiziana of late. If the RP programme is so ground-breaking then perhaps a Nasdaq listing is called for?
And, finally, & again for those with greater scientific i pose this question:
Orgenesis has its roots in cell based programmes - it recently sold its cell manufacturing operations - it currently has $97m in cash against a market cap of some $125m- its programmes cover Exosomes - a claimed flagship programme in diabetes - a recently purchased an anti- viral company with a close to market product & a developing pipeline - rights over some of UK listed Hemogenyx' programmes - a well regarded CEO & Professor Sarah Ferber as a guiding light. A wealth of announcements but very difficult for a layperson to get to grips with. This is not an attempt to ramp; indeed not really possible from this side of the pond - just interested in other opinions. Is this one of those American "sleeping beauties" that will suddenly make the key announcement & go through the roof on the way to becoming a pharma megastar or nothing more than a chimera?
& finally, finally, could Orgenisis find that RENE has attractions as a target?
I will stick to my opinion on this one - + Galleon obviously see value here.
The transformation of Topps is gathering pace. As the Government's push for a house building blitz gathers traction they will be in a sweet spot. Profit expected for the full year & net cash on the Balance Sheet.
Three cheers for Topps & Onwards & Upwards i say ...
Another excellent contract, cementing Galliford's reputation in the North of England.
Utterly amazing that the market pushes companies higher that have & remain in the eye of the Covid storm & the long-term changes that this has unleashed and yet totally ignores a company selling for less than its cash balances & in a construction sweet spot. "Build, build, build" is the Government's mantra & yet Galliford, a major beneficiary sells for a pittance in share price terms.
Time for a re-rate methinks.
I admit that this may only be "flying a kite". BUT: Sosander is on-line only with a particular style & target market & with a Market Cap of some £32M. Quiz has a Cap of only some £8m. Both have cash in the bank. Quiz have dramatically reduced their store estate whilst retaining the gems in their portfolio. In so doing they have significantly increased the proportion of on-line sales. Quiz offerings target a different segment of the market than SOS, just slightly older & more middle class. Seems to be that this could be a marriage made in heaven.
When in doubt i consult my budgerigar. "Hey, Budgie", i said, "What do you think of Reneuron?"
"Cheap, Cheap", he replied.
I wonder if a business combination of QUIZ & SOSANDER is in the wind?
Yes, undercarriage: Good update - should see the price above £1 today & a decent uptrend established.
Some investors obviously think of themselves as miners. They have drilled deeply into the quarterly report & assiduously identified every possible negative. Trouble is that in so doing they have short-sightedly ignored the very considerable positives.
But, this provides an unexpected further buying opportunity for the long sighted. So, I say, "Thank-you".
Why no mention of Zcash ?
On a more positive note I reckon that if BTC is seen to have established a base at $11250 then this should support an Argo price going forward of 8 - 10p. BUT with BTC the fly in the ointment is, of course, the volatility which is why Argo acts like a "Puppet on a string".
So, the metallurgical tests soon to commence & expected by end of 2020. The company have their objectives which they seem confident will be validated. The quote i like is:
"If Blencowe are able to deliver a concentrate with these properties it will have a graphite resource of considerable value"
This company promises to be a Little Gem (and no, i do not mean a lettuce).
The question here is not over the quality of the science but as to whether Genedrive are just destined to be too late in this particular game.
Reading between the lines says more than the lines themselves. Why not wait for some results of the analyses taking place?
Also the repricing of 2.5million of options. WHY? It is not open to any PI to buy shares in any company & then "reprice" the purchase at a future date. This is "Heads they win - Tails they win" for directors & leaves an unpleasant taste in the mouth. After all, if the investment case is as good as they suggest, what is the rationale for repricing?
..... I can now answer my own question. No ! - the persistent sellers are not yet done.
The question that I ask myself today is, "Are the persistent sellers now done". Let's hope so and then the underlying value of BZT's assets can start to be reflected in the SP.
The market greets all of these update announcements from Integumen with a big yawn. It's like someone having a house built and looking at the progress each day & just giving a grunt at the extra layers of bricks or the windows going in or the roof going on. And then suddenly, in all it's glory, it is complete. They stop and stare, rub their eyes. Yes, it is complete - all the effort, all the wait has been worthwhile. That is the journey we are on.
Agreed OWJ89: I see range additions & perhaps bolt on acquisitions as the likely strategy together with a laser like focus on marketing, customer service & cost control.
On 22 June i posted:
"The trick [IMO} will be to resist taking profits as an upwards trend begins to be established"
I remain of that opinion. Cheryl Calverly, in my opinion, is like the star striker plucked from minor league football by a Championship team & that then propels them into the Premiership.